SCHEMBL6755690

SCHEMBL6755690

N=C(Nc1cccc(NC(=O)/C=C/c2ccccc2Cl)c1)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.69
RAB9A P51151 6/20 0.69
NPC1 O15118 5/20 0.69
MAOB P27338 3/20 0.69
KMT2A Q03164 7/20 0.67
SMN1; SMN2 Q16637 5/20 0.67
MEN1 O00255 5/20 0.67
PKM P14618 1/20 0.67
NFKB1 P19838 1/20 0.67
NFKB2 Q00653 1/20 0.67
RELA Q04206 1/20 0.67
TP53 P04637 3/20 0.59
THRB P10828 1/20 0.59
MAOA P21397 2/20 0.57
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
ALDH1A1 P00352 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6756826 0.94 MAPT (0.71) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL6756800 0.92 MAPT (0.64) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL8059586 0.86 MAPT (0.74) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL8059583 0.86 MAPT (0.74) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL7462338 0.86 MAPT (0.59) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL7462343 0.86 MAPT (0.59) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL6757912 0.86 MAPT (0.59) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL6757910 0.85 MAPT (0.53) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL6755771 0.84 RAB9A (0.54) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL6756696 0.84 MAPT (0.60) MAPTRAB9ANPC1MAOBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087798-A1 Novel amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 US disclosed
EP-1264820-A1 NOVEL AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087798-A1 Novel amide compounds H1-2, H1-0, H1-3 MAPT 3247/4885RAB9A 1818/4885NPC1 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.